Qualified subjects will attend a screening visit, a surgical visit (Day 0), and 8 scheduled postoperative visits at Day 1, Day 7, Month 1, Month 3, Month 6, Month 12, Month 18, and Month 24.
This study was initiated by Ivantis, Inc. Ivantis was acquired by Alcon Research, and Alcon assumed sponsorship of the study in November 2022.
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
An operable, age-related cataract with best corrected visual acuity (BCVA) of 20/40 or worse;
Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications;
Optic nerve appearance characteristic of glaucoma;
You may not be if
Closed angle forms of glaucoma;
Congenital or developmental glaucoma;
Secondary glaucoma;
Use of more than 4 ocular hypotensive medications;
Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery;
Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal;